Dr. Mukesh Verma is Chief of the Epidemiology and Genomics Research Program’s (EGRP) Methods and Technologies Branch (MTB), and oversees its research portfolio and initiatives that focus on methods to address epidemiologic data collection, study design and analysis, and to modify technological approaches developed in the context of other research endeavors for use as biomarkers and methods to understand cancer susceptibility. He led the efforts to stimulate and evaluate research in implication of omics approaches to understand cancer etiology. He represents NCI in Common Fund Programs on (1) Epigenomics (https://commonfund.nih.gov/epigenomics), (2) Metabolomics (https://commonfund.nih.gov/metabolomics), and (3) Molecular Transducers of Physical Activity (https://commonfund.nih.gov/moleculartransducers); and (4) congressionally mandated program on Environmental Influences on Child Health Outcome (ECHO) ( https://www.nih.gov/echo ). Since joining the NCI, he sought to champion the visibility of and investment in cancer epigenetics research both within the Institute and across other federal and non-governmental agencies, and to raise public awareness about controlling cancer. He has received NCI Director’s award five times. Dr. Verma is a member of the Editorial Board of the J. of Personalized Medicine, J. of Clinical Epigenetics, and Technologies in Cancer Research and Treatment. He is a member of the Cancer Epigenetics Society. Dr. Mukesh Verma holds a M.Sc. from Pantnagar University and a Ph.D. from Banaras Hindu University. He did postdoctoral research at George Washington University and was a faculty member at Georgetown University Medical Center. He has published 183 research articles and reviews and edited five books in cancer biomarkers, epigenetics and epidemiology field. He has received Director’s award for his contribution in understanding cancer etiology and promoting novel approaches in controlling cancer.